Litcius/Paper detail

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Peter Borchmann, Annette Plütschow, Carsten Kobe, Richard Greil, Julia Meißner, Max S. Topp, Helmut Ostermann, Judith Dierlamm, Johannes Mohm, Julia Thiemer, Martin Sökler, Andrea Kerkhoff, Miriam Ahlborn, Teresa Halbsguth, Sonja Martin, Ulrich Keller, Stefan Balabanov, Thomas Pabst, Martin Vogelhuber, Andreas Hüttmann, Martin Wilhelm, Josée M. Zijlstra, Alden A. Moccia, Georg Kuhnert, Paul J. Bröckelmann, Bastian von Tresckow, Michael Fuchs, Beate Klimm, Andreas Rosenwald, Hans Theodor Eich, Christian Baues, Simone Marnitz, Michael Hallek, Volker Diehl, Markus Dietlein, Andreas Engert

2021The Lancet Oncology168 citationsDOI

Topics & Concepts

MedicineStage (stratigraphy)Open labelRadiation therapyHodgkin lymphomaLymphomaOncologyInternal medicineRadiologyNuclear medicineRandomized controlled trialBiologyPaleontologyLymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial | Litcius